Please login to the form below

Not currently logged in
Email:
Password:

Caisson Biotech appoints Glenn Nedwin as CEO and president

Will lead company as it enters deal with Novo Nordisk

Caisson Biotech has announced former Novozymes president Glenn Nedwin as the company's CEO and president.

He will lead the US biotech as it looks to make the most of a multi-million dollar technology access and license agreement with Novo Nordisk agreed in May, 2012.

“Glenn's comprehensive background in operations, business and product development, and market focus will take Caisson to the next level,” said Thomas Harlan, president of Emergent Technologies – the parent company of Caisson.

Nedwin spent 14 years as president of Danish biotech Novozymes from 1992 to 2006, co-founding the company's US R&D headquarters.

He later joined Danisco as executive VP of its Genencor division, where he was responsible for the technical enzyme business unit.

During this period, he was a member of the team that discovered TNF-alpha and -beta, among other human cytokines.

Most recently, Nedwin was president of the human therapeutics division of Intrexon.

“I am very excited to join Caisson Biotech as CEO and president,” said Nedwin. “Caisson's novel, natural HEPtune drug delivery technology for improved drug performance perfectly fits the needs of the pharmaceutical industry.

“We are seeking additional corporate partners for our technology and we intend to become a leader in drug delivery.”

In addition to his role at Caisson, Nedwin is also a board member of Emergent Technologies and co-editor in chief of the journal Industrial Biotechnology.

24th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health4Brands

At H4B, we are an energetic new team with fresh ideas, but we have over 275 years of combined experience...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....